Endovia Health Sciences, Inc. 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS During the three months ended March 31, 2022, we issued 550,000 shares of common stock in exchange for services, 2,300,000 shares pursuant to our public offering to increase working capital, and 223,596 shares were issued on convertible instruments. For the three-month-ended June 30, 2022 we issued 500,000 shares in exchange for service provided that were valued at a fair market value stock price based on the agreement date and 100,000 shares for cash. During the three-months ended September 30, 2022 we issued 2,000,000 shares pursuant to our public offering to support inventory increases. The Company also issued 380,959 shares in settlement of litigation. We recognized share-based compensation and warrant expense for the nine-months ended September 30, 2022 of $6,717,504 which is classified within non-cash compensation on our Condensed Consolidated Statements of Operations. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. ITEM 4. MINE SAFETY DISCLOSURES No disclosure required.